FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FOG-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FOG-001 overview

FOG-001 is under development of for the treatment of metastatic solid tumors like colorectal cancer, non-small cell lung cancer, gastric cancer and gastroesophageal junction carcinoma. The therapeutic candidate is a cell-penetrating miniprotein (CPMPs) which combines the target-engagement power of biologics with the cell-entry ability of small molecules. It acts by targeting catenin beta 1 (CTNNB1). It is administered through intravenous route.

Fog Pharmaceuticals overview

Fog Pharmaceuticals (Fog) is a biopharmaceutical company that discovers and develops next-generation peptide inhibitors that target traditionally undruggable intracellular protein-protein interactions. The company’s proprietary Helicon polypeptides are used for rapid renal clearance and to achieve long plasma and tissue residence times, providing pharmacokinetic profiles that enable sustained target coverage. Fog utilizes helix hyperstabilization chemistry and multiplexed drug optimization technology, artificial intelligence including deep learning, and machine learning to discover helicon peptide therapeutics. It also develops cell-penetrating mini proteins (CPMPs), a new class of drugs to develop new cancer treatments. Fog is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of FOG-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.